ImmunoGen, Inc. Announces Clinical Data Presentations At The 54th ASH Annual Meeting And Exposition

ImmunoGen, Inc . (NASDAQ: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that there will be clinical data presentations on two compounds that utilize the Company’s TAP technology at the 54 th annual meeting of the American Society of Hematology (ASH) to be held December 8-11, 2012 in Atlanta, GA.

“With ten TAP compounds now in clinical testing – and more in development behind these – we expect an increasing amount of clinical data to be reported on TAP compounds for the foreseeable future,” commented Daniel Junius, President and CEO. “At this year’s annual meeting of ASH, clinical findings will be reported with both our IMGN901 compound and Biotest’s BT-062 compound. Over the course of 2013, we expect data presentations with TAP compounds for the treatment of a number of types of solid tumors as well as additional data to be reported for hematological malignancies.”

IMGN901 Oral Presentation
  • Title: “Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) In Combination with Lenalidomide (Len) and Dexamethasone (Dex) In Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)” (Abstract #728).
  • When/where: Dec. 10 at 4:45 pm ET in the Thomas Murphy Ballroom 2-3 (Session #653).

BT-062 Poster Presentation
  • Title: “BT062, An Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity” (Abstract #4042).
  • When/where: Dec. 10 from 6:00-8:00 pm ET in Hall B1-B2 (Session #653; Poster III).

About IMGN901

IMGN901 is wholly owned by ImmunoGen and consists of the Company's CD56-targeting lorvotuzumab antibody with its DM1 cancer-cell killing agent attached using one of its engineered linkers.

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

7 Stocks Under $10 Making Big Up Moves

Strong On High Relative Volume: Immunogen (IMGN)